Malignant Airway Obstruction and the Use of Nd:YAG Laser: A Systematic Review on Its Efficacy and Safety.
airway stenosis
laser treatment
malignant airway obstruction
nd:yag laser
respiratory tract malignancy
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
30
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Endobronchial malignancies with significant airway obstruction can lead to multiple complications including pneumonia, and atelectasis over a period of time. Various intraluminal treatments have proven their value in palliative treatment for advanced malignancies. Nd:YAG (neodymium-doped yttrium aluminum garnet; Nd:Y3Al5O12) laser has established its role as a major palliative intervention due to its minimal side effects and improvement in quality of life by relieving local symptoms. The systematic review was conducted with the goal of elucidating the patient characteristics, pre-treatment parameters, clinical outcomes, and possible complications resulting from the use of the Nd:YAG laser. A thorough literature search for relevant studies was conducted on PubMed, Embase, and Cochrane Library from the inception of the idea to November 24, 2022. Our study included all original studies including retrospective studies and prospective trials, but excluded case reports, case series with less than 10 patients, and studies with incomplete or irrelevant data. A total of 11 studies were included in the analysis. The primary outcomes focused on the evaluation of pulmonary functional tests, postprocedural stenosis, blood gas parameters after the procedure, and survival outcomes. Improvement in clinical status, improvement in objective scale for dyspnea, and complications were the secondary outcomes. Our study shows that Nd:YAG laser treatment is an effective form of palliative treatment to provide subjective and objective improvement in patients with advanced and inoperable endobronchial malignancies. Due to the heterogeneous study populations in the studies reviewed and the presence of many limitations, more studies are still warranted to reach a definitive conclusion.
Identifiants
pubmed: 36874755
doi: 10.7759/cureus.34434
pmc: PMC9979269
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e34434Informations de copyright
Copyright © 2023, Umar et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Chest. 1999 Oct;116(4):1108-12
pubmed: 10531180
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
Diagn Ther Endosc. 1999;5(3):161-6
pubmed: 18493498
Ann Thorac Med. 2012 Oct;7(4):233-7
pubmed: 23189101
Eur Arch Otorhinolaryngol. 2003 Apr;260(4):219-22
pubmed: 12709807
Thorax. 1981 Mar;36(3):175-8
pubmed: 7197061
Br Med J (Clin Res Ed). 1983 Jan 1;286(6358):12-6
pubmed: 6401440
Thorax. 1997 Mar;52(3):281-3
pubmed: 9093347
West J Med. 1984 Mar;140(3):393-7
pubmed: 6201011
J Thorac Cardiovasc Surg. 2006 Jun;131(6):1236-42
pubmed: 16733151
West J Med. 1990 Oct;153(4):385-9
pubmed: 2244372
Semin Surg Oncol. 1989;5(1):38-47
pubmed: 2711084
Lasers Med Sci. 2006 Dec;21(4):186-91
pubmed: 17003957
J Thorac Oncol. 2007 Jan;2(1):59-64
pubmed: 17410011
Thorax. 1987 Sep;42(9):656-60
pubmed: 3686456
Eur Respir J. 1999 Oct;14(4):800-5
pubmed: 10573224
Acta Clin Belg. 1997;52(6):371-80
pubmed: 9489133